Novo Shares Drop as Ozempic Pill Fails Alzheimer’s Trial

Madison Muller, Bloomberg News health reporter, says that the failure of a long-shot trial to see if the pill form of Novo Nordisk's weight loss drug Ozempic impacted Alzheimer's was...

By Bloomberg Markets · Bloomberg Markets

Madison Muller, Bloomberg News health reporter, says that the failure of a long-shot trial to see if the pill form of Novo Nordisk's weight loss drug Ozempic impacted Alzheimer's was the latest in a long string of disappointments for investors into the pharmaceutical company. Novo Nordisk is down over 50% on the year. (Source: Bloomberg)